PubRank

Richard Gorlick

Author PubWeight™ 169.81‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007 5.28
2 The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004 4.28
3 Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004 3.34
4 Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010 2.99
5 Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005 2.31
6 Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet 2013 2.21
7 Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006 2.19
8 Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 2008 1.95
9 Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004 1.93
10 Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 2010 1.92
11 Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008 1.84
12 Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol 2007 1.81
13 High-dose methotrexate in osteosarcoma: let the questions surcease--time for final acceptance. J Clin Oncol 2008 1.81
14 Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 1.71
15 Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 2007 1.71
16 The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A 2003 1.69
17 Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification. Cancer Biol Ther 2004 1.67
18 New targets and approaches in osteosarcoma. Pharmacol Ther 2012 1.67
19 Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer 2010 1.66
20 Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008 1.66
21 Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005 1.66
22 An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 2005 1.60
23 Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 2002 1.56
24 Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 1.55
25 Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet 2003 1.54
26 Loss of antibody titers and effectiveness of revaccination in post-chemotherapy pediatric sarcoma patients. Pediatr Blood Cancer 2007 1.48
27 Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004 1.48
28 Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma. J Clin Oncol 2003 1.44
29 Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective. Pediatr Blood Cancer 2010 1.42
30 Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 2004 1.40
31 Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 2003 1.36
32 Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 2004 1.34
33 Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther 2010 1.34
34 Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 2002 1.34
35 Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer 2012 1.33
36 FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 2006 1.32
37 R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 2010 1.31
38 Mesenchymal chondrosarcoma: clinicopathologic study of 20 cases. Arch Pathol Lab Med 2012 1.31
39 Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol 2011 1.30
40 Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res 2002 1.29
41 Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol 2012 1.27
42 Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 1.26
43 Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 1.25
44 Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003 1.25
45 Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010 1.24
46 Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 2004 1.24
47 Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 2003 1.22
48 Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis. Cancer 2006 1.21
49 Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008 1.20
50 Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res 2007 1.20
51 Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 2013 1.16
52 Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res 2008 1.16
53 Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 1.14
54 Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 2009 1.14
55 Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2011 1.13
56 Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther 2009 1.12
57 Development of IGF-IR Inhibitors in Pediatric Sarcomas. Curr Oncol Rep 2009 1.10
58 Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 2007 1.09
59 Genetically transforming human mesenchymal stem cells to sarcomas: changes in cellular phenotype and multilineage differentiation potential. Cancer 2009 1.08
60 Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 2005 1.08
61 Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer 2009 1.08
62 Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer 2010 1.05
63 Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res 2009 1.05
64 Hypoxia markers in human osteosarcoma: an exploratory study. Clin Orthop Relat Res 2008 1.05
65 Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010 1.05
66 Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011 1.04
67 Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 2010 1.03
68 Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2012 1.03
69 Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer 2010 1.03
70 Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 2002 1.03
71 Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer 2013 1.02
72 Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer 2010 1.00
73 mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Mol Cancer Ther 2003 1.00
74 The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2004 0.99
75 Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2011 0.98
76 Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003 0.97
77 A Decade in Banking Ewing Sarcoma: A Report from the Children's Oncology Group. Front Oncol 2013 0.97
78 Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. J Orthop Res 2008 0.96
79 The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res 2007 0.95
80 Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer 2009 0.95
81 A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol 2013 0.95
82 Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer 2010 0.94
83 Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Clin Cancer Res 2008 0.94
84 Cell proliferation of cultured human cancer cells are affected by the elevated tumor pressures that exist in vivo. Ann Biomed Eng 2005 0.92
85 Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer 2011 0.91
86 Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2012 0.91
87 Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. BMC Cancer 2008 0.91
88 Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 2014 0.90
89 Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther 2009 0.90
90 Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Cancer 2005 0.89
91 IGF-1R targeted treatment of sarcoma. Lancet Oncol 2009 0.89
92 Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. Oncol Res 2004 0.88
93 Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study. J Pediatr Hematol Oncol 2003 0.88
94 Cell surface receptor expression patterns in osteosarcoma. Cancer 2011 0.88
95 Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 0.88
96 Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Eur J Cancer 2013 0.87
97 Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer 2014 0.87
98 Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer 2011 0.87
99 Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res 2003 0.87
100 Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatr Blood Cancer 2010 0.87
101 Malignant ectomesenchymoma in the wrist of a child: case report and review of the literature. Int J Surg Pathol 2005 0.86
102 Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr Blood Cancer 2011 0.85
103 VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI. Clin Orthop Relat Res 2004 0.85
104 Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer 2010 0.85
105 Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother Pharmacol 2009 0.85
106 Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer 2012 0.85
107 HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. Pediatr Blood Cancer 2014 0.84
108 Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer 2011 0.84
109 Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer 2011 0.84
110 Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2013 0.83
111 Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011 0.83
112 Quality of life following amputation or limb preservation in patients with lower extremity bone sarcoma. Front Oncol 2013 0.83
113 Polymorphisms and methylation of the reduced folate carrier in osteosarcoma. Clin Orthop Relat Res 2008 0.83
114 A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation. Pediatr Blood Cancer 2014 0.83
115 Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer 2014 0.83
116 Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer 2013 0.82
117 Tumour interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. Ann Acad Med Singapore 2009 0.82
118 Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer 2011 0.82
119 Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study. Pediatr Blood Cancer 2013 0.81
120 Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas. Biochim Biophys Acta 2004 0.81
121 Impairment of methotrexate transport is common in osteosarcoma tumor samples. Sarcoma 2010 0.81
122 Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer 2013 0.81
123 Initial testing of lenalidomide by the pediatric preclinical testing program. Pediatr Blood Cancer 2011 0.80
124 The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue. Pediatr Blood Cancer 2008 0.80
125 Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatr Blood Cancer 2009 0.80
126 Future directions in the treatment of osteosarcoma. Curr Opin Pediatr 2016 0.79
127 An 19F magnetic resonance-based in vivo assay of solid tumor methotrexate resistance: proof of principle. Clin Cancer Res 2005 0.79
128 Predictive properties of DNA methylation patterns in primary tumor samples for osteosarcoma relapse status. Epigenetics 2015 0.79
129 Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma. Clin Orthop Relat Res 2016 0.79
130 Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. Pediatr Blood Cancer 2012 0.79
131 Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011 0.79
132 HER-2 involvement in osteosarcoma. Adv Exp Med Biol 2014 0.78
133 Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2013 0.78
134 Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatr Blood Cancer 2014 0.77
135 Identification of prognostic markers in bone sarcomas using proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res 2003 0.77
136 Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatr Blood Cancer 2014 0.77
137 Immune approaches to treating osteosarcoma. Cancer Biol Ther 2009 0.77
138 Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011 0.77
139 Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 2014 0.76
140 Variability in the reported management of pulmonary metastases in osteosarcoma. Cancer Med 2015 0.76
141 β-Catenin Does Not Confer Tumorigenicity When Introduced into Partially Transformed Human Mesenchymal Stem Cells. Sarcoma 2012 0.76
142 HER-2 targeted treatment of osteosarcoma: the challenges of developing targeted therapy and prognostic factors for rare malignancies. Expert Opin Pharmacother 2010 0.76
143 High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura. Br J Haematol 2002 0.76
144 Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. Cancer 2009 0.75
145 Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2013 0.75
146 Vulvar fibromatosis: a clinical enigma. J Pediatr Hematol Oncol 2015 0.75
147 Collaborations between SSO and the Connective Tissue Oncology Society (CTOS) series. Ann Surg Oncol 2015 0.75
148 Current practice managements regarding thromboembolic prophylaxis within the pediatric sarcoma patient population. J Pediatr Hematol Oncol 2013 0.75